ReviewCancers2023
Overview of Molecular Detection Technologies for
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Pragmatic Management of EGFR-Mutant NSCLC After Progression on Osimertinib: Canadian Expert Perspectives.Current oncology (Toronto, Ont.) · 2026Review
- Pitfalls in Detecting MET Exon 14 Skipping Variants by DNA- and RNA-Based Next-Generation Sequencing Technologies in a Large Real-World Cohort and Results of the First Multinational External Quality Assessment Schemes.The Journal of molecular diagnostics : JMD · 2026Article
- TargetingTranslational lung cancer research · 2026Article
- Targeting MET in advanced and metastatic non-small cell lung cancer: a literature review of the current landscape.Translational cancer research · 2025Review
- MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer.Cancers · 2025Article
- Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy.Clinical and experimental medicine · 2025Article
- Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.Cancer biology & medicine · 2025Article
- NGS coverage accurately predictsFrontiers in oncology · 2025Article
- ALK-tyrosine kinase inhibitor intrinsic resistance due toTranslational lung cancer research · 2024Article
- Targeting the MET gene: unveiling therapeutic opportunities in immunotherapy within the tumor immune microenvironment of non-small cell lung cancer.Therapeutic advances in medical oncology · 2024Review
- The rapidly changing field of predictive biomarkers of non-small cell lung cancer.Pathology oncology research : POR · 2024Review
- Up-regulation by overexpression of c-MET in fibroblastic foci of usual interstitial pneumonia.Pathologica · 2023Article
- Article
- Real-World Data on Combined EGFR-TKI and Crizotinib Treatment for Acquired and De NovoInternational journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MET tyrosine kinase receptor pathway activation has become an important actionable target in solid tumors. Aberrations in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.